Vetter Opens New Sales Office at Illinois Science + Technology Park in Suburban Chicago

In keeping with its strategy of U.S. growth and expansion, Vetter, a specialist in aseptically prefilled drugdelivery systems, today announced that it has opened a new sales office at the Illinois Science +Technology Park in Skokie. The office will be managed by Mr. Troy Carpenter, who was appointed as President of Vetter Pharma International USA Inc. The new office replaces its Yardley, Pennsylvania sales office, founded in 1983 as Vetter Pharma-Turm Inc. The establishment of the new office in the Midwest region, considered an emerging "hotspot" in biotechnology, is consistent with the company's stated objective for worldwide growth by focusing on the emerging pharmaceutical and biotechnology market in North America. The office, to be officially known as Vetter Pharma International USA Inc., is a wholly owned subsidiary of Vetter Pharma International GmbH, which is responsible for Vetter's sales and marketing as well as customer service functions. In 2009, Vetter announced the creation of its first U.S. manufacturing facility, also located at the Illinois Science + Technology Park. The facility - an expansion of Vetter Development Service - is scheduled to be operational in the beginning of the fourth quarter of 2010.

Troy Carpenter will manage Vetter key account managers across the United States who are responsible for all sales and business development activities in North America. Previously, Mr. Carpenter was Director, Key Account Management for Sartorius-Stedim Biotech where he was responsible globally for a number of important accounts in the pharmaceutical and biotech market. He also acted as key account manager for Vetter Pharma-Turm from 2002 to 2007, being responsible for sales and business development in the U.S. western region.

"We are very pleased to have Troy rejoin Vetter as our new President of Vetter Pharma International USA Inc.," said Peter Soelkner, Vetter Managing Director. "Troy's extensive knowledge of the U.S. pharmaceutical and biotechnology markets is a tremendous asset to Vetter and will complement our key account management concept of working with clients from early development through commercial manufacturing and global market supply. Additionally, Troy's previous work with companies in our industry clearly demonstrates his ability to successfully develop and execute sales strategies and manage account teams for toptier companies."

As with the new Chicago manufacturing facility locating the new sales office at the Illinois Science + Technology Park offers distinct advantages for both Vetter and its clients, around half of which are based in North America. Ease of access to major airports and, soon, direct train access for customers will help support the company's stated "partnership approach" and is further demonstration of its firm strategic commitment to the North American market.